Relapsed / Refractory AML
15 clinical trials · Condition
◉ Watch Relapsed / Refractory AML
| Record | Firm | Date |
|---|---|---|
| A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies (NCT05428969) | Faron Pharmaceuticals Ltd | 2022-06-02 |
| Study to Evaluate the Efficacy of Uproleselan in Combination With Chemotherapy in Chinese Patients With R/R AML (NCT05054543) | Apollomics Inc. | 2021-11-17 |
| NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDS (NCT04623944) | Nkarta, Inc. | 2020-09-21 |
| CD123/CLL1 CAR-T Cells for R/R AML (STPHI_0001) (NCT03631576) | Fujian Medical University | 2018-08-10 |
| A Phase 1 Study of AMG 330 in Subjects With Myeloid Malignancies (NCT02520427) | Amgen | 2015-08-31 |
| POETIC Plerixafor as a Chemosensitizing Agent for Relapsed Acute Leukemia and MDS in Pediatric Patients (NCT01319864) | Seattle Children's Hospital | 2011-03-01 |
| The Pharmacokinetics and Cardiac Properties of Elacytarabine (CP-4055) (NCT01258816) | Clavis Pharma | 2010-10-01 |
Track Relapsed / Refractory AML automatically
Every clearance here is in the API, with alerts when new ones post.